Announcement • Jun 30
Fuan Pharmaceutical (Group) Co., Ltd. to Report First Half, 2026 Results on Aug 27, 2026 Fuan Pharmaceutical (Group) Co., Ltd. announced that they will report first half, 2026 results on Aug 27, 2026 Declared Dividend • May 23
Dividend of CN¥0.05 announced Shareholders will receive a dividend of CN¥0.05. Ex-date: 28th May 2026 Payment date: 28th May 2026 Dividend yield will be 1.8%, which is about the same as the industry average. Sustainability & Growth Dividend is not covered by earnings (141% earnings payout ratio). However, it is well covered by cash flows (30% cash payout ratio). The dividend has increased by an average of 7.7% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 57% to bring the payout ratio under control. However, EPS has declined by 21% over the last 5 years so the company would need to reverse this trend. New Risk • Apr 27
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 64% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.4% net profit margin). Announcement • Apr 27
Fuan Pharmaceutical (Group) Co., Ltd., Annual General Meeting, May 19, 2026 Fuan Pharmaceutical (Group) Co., Ltd., Annual General Meeting, May 19, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Chongqing China Announcement • Mar 31
Fuan Pharmaceutical (Group) Co., Ltd. to Report Q1, 2026 Results on Apr 27, 2026 Fuan Pharmaceutical (Group) Co., Ltd. announced that they will report Q1, 2026 results on Apr 27, 2026 Announcement • Dec 31
Fuan Pharmaceutical (Group) Co., Ltd. to Report Fiscal Year 2025 Results on Apr 27, 2026 Fuan Pharmaceutical (Group) Co., Ltd. announced that they will report fiscal year 2025 results on Apr 27, 2026 Reported Earnings • Oct 28
Third quarter 2025 earnings released: EPS: CN¥0.041 (vs CN¥0.07 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.041 (down from CN¥0.07 in 3Q 2024). Revenue: CN¥394.9m (down 30% from 3Q 2024). Net income: CN¥53.1m (down 38% from 3Q 2024). Profit margin: 14% (down from 15% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Announcement • Sep 30
Fuan Pharmaceutical (Group) Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025 Fuan Pharmaceutical (Group) Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025 Announcement • Aug 28
Fuan Pharmaceutical (Group) Co., Ltd. Proposes Interim Cash Dividend for 2025 Fuan Pharmaceutical (Group) Co., Ltd. at 1st Extraordinary General Meeting of 2025 to be held on 15 September 2025 proposed 2025 interim profit distribution plan of Cash dividend/10 shares (tax included) CNY 0.20000000. Reported Earnings • Aug 27
Second quarter 2025 earnings released: EPS: CN¥0.04 (vs CN¥0.08 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.04 (down from CN¥0.08 in 2Q 2024). Revenue: CN¥452.8m (down 27% from 2Q 2024). Net income: CN¥44.1m (down 53% from 2Q 2024). Profit margin: 9.7% (down from 15% in 2Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Announcement • Jul 02
Fuan Pharmaceutical (Group) Co., Ltd. to Report First Half, 2025 Results on Aug 27, 2025 Fuan Pharmaceutical (Group) Co., Ltd. announced that they will report first half, 2025 results on Aug 27, 2025 Board Change • Jun 12
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Zhiqiang Liu was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Declared Dividend • May 23
Dividend of CN¥0.05 announced Dividend of CN¥0.05 is the same as last year. Ex-date: 28th May 2025 Payment date: 28th May 2025 Dividend yield will be 1.2%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (22% earnings payout ratio) but not adequately covered by cash flows (96% cash payout ratio). The dividend has increased by an average of 4.1% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 76% to shift the payout ratio to a potentially unsustainable range, which is more than the 1.2% EPS decline seen over the last 5 years. New Risk • May 12
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Announcement • Apr 25
Fuan Pharmaceutical (Group) Co., Ltd. Proposes Final Cash Dividend for the Year 2024 Fuan Pharmaceutical (Group) Co., Ltd. announced on 25 April 2025 the profit distribution proposal for 2024 as follows: final cash dividend per 10 shares (tax included) of CNY 0.50000000. Announcement • Apr 24
Fuan Pharmaceutical (Group) Co., Ltd., Annual General Meeting, May 15, 2025 Fuan Pharmaceutical (Group) Co., Ltd., Annual General Meeting, May 15, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Chongqing China Announcement • Mar 31
Fuan Pharmaceutical (Group) Co., Ltd. to Report Q1, 2025 Results on Apr 24, 2025 Fuan Pharmaceutical (Group) Co., Ltd. announced that they will report Q1, 2025 results on Apr 24, 2025 Announcement • Dec 31
Fuan Pharmaceutical (Group) Co., Ltd. to Report Fiscal Year 2024 Results on Apr 24, 2025 Fuan Pharmaceutical (Group) Co., Ltd. announced that they will report fiscal year 2024 results on Apr 24, 2025 Board Change • Dec 01
High number of new directors Independent Director Zhiqiang Liu was the last director to join the board, commencing their role in 2024. Reported Earnings • Oct 25
Third quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.07 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.07 (in line with 3Q 2023). Revenue: CN¥562.3m (down 14% from 3Q 2023). Net income: CN¥85.1m (down 6.4% from 3Q 2023). Profit margin: 15% (up from 14% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Announcement • Sep 30
Fuan Pharmaceutical (Group) Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024 Fuan Pharmaceutical (Group) Co., Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to CN¥4.75, the stock trades at a trailing P/E ratio of 19.7x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total returns to shareholders of 16% over the past three years. Reported Earnings • Aug 29
Second quarter 2024 earnings released: EPS: CN¥0.08 (vs CN¥0.07 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.08 (up from CN¥0.07 in 2Q 2023). Revenue: CN¥623.6m (down 2.2% from 2Q 2023). Net income: CN¥94.0m (up 26% from 2Q 2023). Profit margin: 15% (up from 12% in 2Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Announcement • Jun 29
Fuan Pharmaceutical (Group) Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024 Fuan Pharmaceutical (Group) Co., Ltd. announced that they will report first half, 2024 results on Aug 29, 2024 Announcement • May 29
Fuan Pharmaceutical (Group) Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 04 June 2024 Fuan Pharmaceutical (Group) Co., Ltd. announced on 28 May 2024 the 2023 final profit distribution plan to be implemented (A shares): cash dividend per 10 shares (tax included) of CNY 0.50000000. Record date: 03 June 2024. Ex-date: 04 June 2024. Payment date: 04 June 2024. Announcement • Apr 27
Fuan Pharmaceutical (Group) Co., Ltd. Proposes Final Cash Dividend for 2023 Fuan Pharmaceutical (Group) Co., Ltd. announced on 25 April 2024 the profit distribution proposal for 2023 as follows: final cash dividend per 10 shares (tax included) of CNY 0.50000000. Announcement • Apr 26
Fuan Pharmaceutical (Group) Co., Ltd., Annual General Meeting, May 24, 2024 Fuan Pharmaceutical (Group) Co., Ltd., Annual General Meeting, May 24, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Yantai, Shandong China Reported Earnings • Apr 25
First quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.07 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.10 (up from CN¥0.07 in 1Q 2023). Revenue: CN¥809.4m (up 17% from 1Q 2023). Net income: CN¥122.5m (up 42% from 1Q 2023). Profit margin: 15% (up from 12% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Announcement • Mar 30
Fuan Pharmaceutical (Group) Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024 Fuan Pharmaceutical (Group) Co., Ltd. announced that they will report Q1, 2024 results on Apr 25, 2024 Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥3.26, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 25x in the Pharmaceuticals industry in China. Total loss to shareholders of 15% over the past three years. Announcement • Dec 30
Fuan Pharmaceutical (Group) Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024 Fuan Pharmaceutical (Group) Co., Ltd. announced that they will report fiscal year 2023 results on Apr 25, 2024 Reported Earnings • Oct 26
Third quarter 2023 earnings released: EPS: CN¥0.07 (vs CN¥0.04 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.07 (up from CN¥0.04 in 3Q 2022). Revenue: CN¥654.5m (up 3.3% from 3Q 2022). Net income: CN¥91.0m (up 89% from 3Q 2022). Profit margin: 14% (up from 7.6% in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Sep 12
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥4.70, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total loss to shareholders of 25% over the past three years. Reported Earnings • Aug 30
Second quarter 2023 earnings released: EPS: CN¥0.07 (vs CN¥0.04 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.07 (up from CN¥0.04 in 2Q 2022). Revenue: CN¥637.5m (up 6.7% from 2Q 2022). Net income: CN¥74.9m (up 48% from 2Q 2022). Profit margin: 12% (up from 8.5% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. Announcement • May 06
Fuan Pharmaceutical (Group) Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on 12 May 2023 Fuan Pharmaceutical (Group) Co., Ltd. announced final cash dividend of CNY 0.50000000 per 10 shares (tax included) on A Shares for the year 2022. Record date: 11 May 2023, Ex-date: 12 May 2023 and Payment date: 12 May 2023. Reported Earnings • Apr 26
First quarter 2023 earnings released: EPS: CN¥0.07 (vs CN¥0.03 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.07 (up from CN¥0.03 in 1Q 2022). Revenue: CN¥691.0m (up 25% from 1Q 2022). Net income: CN¥86.0m (up 131% from 1Q 2022). Profit margin: 12% (up from 6.7% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Buying Opportunity • Dec 26
Now 22% undervalued Over the last 90 days, the stock is up 13%. The fair value is estimated to be CN¥4.81, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 4.8% over the last 3 years. Meanwhile, the company became loss making. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Geng Chen was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 26
Third quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.06 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.04 (down from CN¥0.06 in 3Q 2021). Revenue: CN¥633.4m (up 4.7% from 3Q 2021). Net income: CN¥48.2m (down 33% from 3Q 2021). Profit margin: 7.6% (down from 12% in 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 31
Second quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.04 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.04 (vs CN¥0.04 in 2Q 2021). Revenue: CN¥597.7m (up 4.5% from 2Q 2021). Net income: CN¥50.6m (up 12% from 2Q 2021). Profit margin: 8.5% (up from 7.9% in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 15% per year. Reported Earnings • Apr 27
First quarter 2022 earnings: EPS and revenues exceed analyst expectations First quarter 2022 results: EPS: CN¥0.03 (down from CN¥0.05 in 1Q 2021). Revenue: CN¥552.7m (down 15% from 1Q 2021). Net income: CN¥37.3m (down 39% from 1Q 2021). Profit margin: 6.7% (down from 9.5% in 1Q 2021). Revenue exceeded analyst estimates by 46%. Earnings per share (EPS) also surpassed analyst estimates by 26%. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Geng Chen was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 28
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: CN¥0.25 loss per share (down from CN¥0.18 profit in FY 2020). Revenue: CN¥2.45b (up 3.5% from FY 2020). Net loss: CN¥296.9m (down 242% from profit in FY 2020). Revenue exceeded analyst estimates by 46%. Earnings per share (EPS) missed analyst estimates. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Dec 27
Investor sentiment improved over the past week After last week's 23% share price gain to CN¥5.14, the stock trades at a trailing P/E ratio of 31.8x. Average trailing P/E is 36x in the Pharmaceuticals industry in China. Total returns to shareholders of 63% over the past three years. Reported Earnings • Aug 30
Second quarter 2021 earnings released: EPS CN¥0.04 (vs CN¥0.05 in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥572.1m (down 3.0% from 2Q 2020). Net income: CN¥45.2m (down 29% from 2Q 2020). Profit margin: 7.9% (down from 11% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Announcement • May 08
Fuan Pharmaceutical (Group) Co., Ltd. Announces Implementation of Profit Distribution Plan for A Shares for the Year 2020, Payable on 14 May 2021 Fuan Pharmaceutical (Group) Co., Ltd. announced the implementation of profit distribution plan for A shares as cash dividend/10 shares (tax included) of CNY 0.50 for A shares for the year 2020, payable on 14 May 2021. Record date is 13 May 2021 and Ex-date is 14 May 2021. Reported Earnings • Apr 30
First quarter 2021 earnings released: EPS CN¥0.05 (vs CN¥0.06 in 1Q 2020) The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: CN¥649.3m (up 14% from 1Q 2020). Net income: CN¥61.5m (down 10.0% from 1Q 2020). Profit margin: 9.5% (down from 12% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 01
Full year 2020 earnings released: EPS CN¥0.18 (vs CN¥0.25 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥2.37b (down 15% from FY 2019). Net income: CN¥209.4m (down 28% from FY 2019). Profit margin: 8.8% (down from 11% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Announcement • Feb 25
Fuan Pharmaceutical (Group) Co., Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021 Fuan Pharmaceutical (Group) Co., Ltd. announced that they will report fiscal year 2020 results on Mar 31, 2021 Is New 90 Day High Low • Jan 29
New 90-day low: CN¥4.18 The company is down 32% from its price of CN¥6.13 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. Is New 90 Day High Low • Jan 11
New 90-day low: CN¥4.74 The company is down 22% from its price of CN¥6.10 on 13 October 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period. Valuation Update With 7 Day Price Move • Dec 28
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥4.91, the stock is trading at a trailing P/E ratio of 22.4x, down from the previous P/E ratio of 26.4x. This compares to an average P/E of 34x in the Pharmaceuticals industry in China. Total return to shareholders over the past three years is a loss of 12%. Is New 90 Day High Low • Dec 23
New 90-day low: CN¥5.42 The company is down 11% from its price of CN¥6.09 on 24 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period. Announcement • Aug 13
Fuan Pharmaceutical (Group) Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020 Fuan Pharmaceutical (Group) Co., Ltd. announced that they will report first half, 2020 results on Aug 28, 2020 
